June 2016 DAWN Haematology Software E-Newsletter
In this issue:
Work Smarter - DAWN Version 7.9.55
Enter a start date up to a given number of days in the future
In previous versions of DAWN, if you entered a Treatment Plan start date in the future, DAWN prompted you to confirm this was correct. This proved cumbersome for staff who routinely create records for patients due to start tomorrow or next week, but was even more disruptive for the interface which has no way of acknowledging the prompt and so is unable to save the new treatment plan. As a result, the demographics interface message is put on hold.
A new system setting allows you to specify how many days into the future a Treatment Plan start date entry can be before you are prompted to confirm it.
New or amended coded comments are visible to all DAWN instances without the need to unload
On versions of DAWN CH that use load balancing for enhanced performance, when enabled, changes to coded comments were only visible to each load balanced instance of DAWN in which the person who made the change was working. To make the change available to all instances and hence to all users, the system needed to be unloaded and reloaded.
In the latest version of DAWN CH all instances regularly check for new or changed Coded Comments and update their cached libraries automatically. This means a coded comment created in one instance of DAWN is available in all instances within a few minutes.
Patient screen now includes a configurable miscellaneous field
The Contact Info tab under the Personal tab on the patient screen includes a new field you can use to store anything you like, for example: health insurance number, telephone number for use with external telephony system, key code for home visits etc.
The field caption is “Misc” by default but you are able to change this to whatever you want it to be.
For information on any of the latest updates to the DAWN RH system or to enquire about upgrading, contact the support team at firstname.lastname@example.org.
DAWN patient View Button for a concise patient summary
The patient view button in DAWN RH is designed to provide a concise, easily accessible patient summary that can be used for a variety of things including sending to GP's and team meetings.
Customers who make use of the Patient View button are able to save time both gathering patient information and reviewing it from potentially multiple systems.
For more information on the Patient View button, contact the DAWN support team at email@example.com.
Fast and efficient electronic patient referrals
Referring a patient to a consultant for an opinion should be quick, efficient and traceable. If you don't have time to chase your colleagues between clinics but you feel an opinion would keep your patient safe, consider team-working using the referrals functionality within DAWN CH.
DAWN CH's electronic referral functionality enables you to make referrals quickly and easily, making your workflow more efficient, saving you time and providing visibility of the referral.
Contact firstname.lastname@example.org for more information.
Enhance your communication with timed messages from DAWN
The DAWN database can now be configured to generate SMS/text messages or email alerts for patients and healthcare professionals.
Several timed messages can be sent to participating patients to remind them that their next blood monitoring test is due in a few day's time.
The DAWN database can also be set up to prompt the lead nurse or doctor that recent results require review in the DAWN database.
For more information on timed messages (SMS/Text and Email) contact the DAWN support team at email@example.com.
Support and trouble-shooting for your DAWN CH system
Don't forget that there are lots of resources available to customers on the 4S DAWN website that provide support for your DAWN CH system.
You can access these quickly and easily via the following link: http://www.4s-dawn.com/dawn-disease-areas-support-resources/
Did you know...
- What to do if DAWN has stopped working - Troubleshooting Guide
- DAWN CH User Manual
- DAWN CH Safety Manual
- Customer Obligations
- Performance Checklist
- DAWN Interface Troubleshooting Guide
- Interfaces Safety Checklist
Scientists detect gene networks likely to be shared by all CLL patients
Research, involving scientists and doctors at the University of Southampton and Royal Bournemouth Hospital, has identified a network of genes that are likely to be shared by all patients who have chronic lymphocytic leukaemia (CLL).
Furthermore, the study has identified gene networks that are associated with patient survival, which could be identified as targets for treatment.
The study was part of a group of work by an international consortium of biomedical researchers led by the CeMM Research Center, testing the feasibility of epigenetic analysis for clinical diagnostics and precision medicine
Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance
A 60-year-old man who was referred to a palliative care clinic with monoclonal gammopathy of undetermined significance (MGUS)-associated neuropathy, responded to a therapeutic trial of warfarin.
After an interdisciplinary evaluation and informed consent, he was started on warfarin 2.5 mg orally with a target international normalised ratio (INR) of 1.5–2.0. One month later, he reported, ‘pain beginning to improve’.
The patient reported having had improvement of his neuropathic symptoms while taking warfarin postoperatively for thromboprophylaxis 1 year prior, and recurrence of his symptoms after the warfarin was discontinued. The patient was rechallenged with a trial of warfarin, targeting an international normalised ratio of 1.5–2.0. His pain scores decreased from 5/10 to 3/10 at 1 month and symptom improvement was maintained through 24 months of follow-up.
Further studies to help guide the use of warfarin for MGUS-associated neuropathy may be a challenge given the medication's high risk for adverse effects; however, patients with MGUS-associated neuropathy on warfarin therapy for other conditions requiring anticoagulation, should be observed for symptom benefit, potentially guiding future research.
EC approves Imbruvica for first-line treatment of patients with chronic lymphocytic leukaemia
the European Commission (EC) approved Imbruvica (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukaemia (CLL), expanding upon the initial EC approval in October 2014 for certain patients with CLL. This decision comes just one month after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an opinion in favour of the use of Imbruvica for the treatment of adult patients with first-line chronic lymphocytic leukaemia (CLL) in the European Union (EU).
Follow us on our LinkedIn Page!
4S DAWN Clinical Software has a new LinkedIn company page where you can keep up to date with all of the latest news and developments. Follow us and join our LinkedIn community: CLICK HERE